These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 318211)

  • 1. Penetration of cephalothin and cefoxitin into experimental infections with Bacteroides fragilis.
    O'Keefe JP; Tally FP; Barza M; Gorbach SL
    Rev Infect Dis; 1979; 1(1):106-12. PubMed ID: 318211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of cefoxitin and cephalothin therapy of a mixed Bacteroides fragilis and Fusobacterius necrophorum infection in mice.
    Hackman AS; Wilkins TD
    Antimicrob Agents Chemother; 1975 Aug; 8(2):224-5. PubMed ID: 1180547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vivo efficiency of cefamandole and cefoxitin against Bacteroides fragilis.
    Bergeron MG; Gauvreau L; Nguyen BM
    Scand J Infect Dis Suppl; 1980; suppl 25():60-5. PubMed ID: 6937954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of ceftizoxime against Bacteroides fragilis: comparison with benzylpenicillin, cephalothin, and cefoxitin.
    Eley A; Greenwood D
    Antimicrob Agents Chemother; 1981 Sep; 20(3):332-5. PubMed ID: 6272629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro susceptibility of bacteroidaceae to cefoxitin and cephalothin (author's transl)].
    Werner H; Firsching R; Krasemann C
    Infection; 1977; 5(1):13-6. PubMed ID: 856727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical importance of cefoxitin-resistant Bacteroides fragilis isolates.
    Bieluch VM; Cuchural GJ; Snydman DR; Gorbach SL; Tally FP
    Diagn Microbiol Infect Dis; 1987 Jun; 7(2):119-26. PubMed ID: 3652652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of penicillin G during experimental infection with Bacteroides fragilis.
    O'Keefe JP; Tally FP; Barza M; Gorbach SL
    J Infect Dis; 1978 Apr; 137(4):437-42. PubMed ID: 649987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefoxitin and cephalothin: antimicrobial activity, human pharmacokinetics, and toxicology.
    Brumfitt W; Kosmidis J; Hamilton-Miller JM; Gilchrist JN
    Antimicrob Agents Chemother; 1974 Sep; 6(3):290-9. PubMed ID: 15830475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of moxalactam in an animal model of subcutaneous abscesses: penetration into infected sites and in vivo activity against Bacteroides fragilis.
    Bartlett JG; Joiner KA; Dezfulian M; Marien GJ
    Rev Infect Dis; 1982; 4 Suppl():S664-9. PubMed ID: 6218580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of rate of infusion and probenecid on serum levels, renal excretion, and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin.
    Goodwin CS; Raftery EB; Goldberg AD; Skeggs H; Till AE; Martin CM
    Antimicrob Agents Chemother; 1974 Sep; 6(3):338-46. PubMed ID: 15830485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Synergistic effect of thiamphenicol and cephalothin on Bacterioides fragilis (author's transl)].
    Isono M; Aoki M; Kobayashi T; Marui T; Yamada H; Umemura A; Watanabe K; Ueno K
    Jpn J Antibiot; 1981 May; 34(5):647-50. PubMed ID: 7026821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
    Brook I
    J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of 10 antimicrobial agents in experimental infections with Bacteroides fragilis.
    Joiner K; Lowe B; Dzink J; Bartlett JG
    J Infect Dis; 1982 Apr; 145(4):561-8. PubMed ID: 7069236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of beta-lactamase and the permeability barrier on the activity of cephalosporins against members of the Bacteroides fragilis group.
    Malouin F; Lamothe F
    Can J Microbiol; 1987 Mar; 33(3):262-6. PubMed ID: 3105858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of cephalosporins by Bacteroides.
    Tally FP; O'Keefe JP; Sullivan NM; Gorbach SL
    Antimicrob Agents Chemother; 1979 Nov; 16(5):565-71. PubMed ID: 525995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Microbiological evaluation of cefoxitin, a new beta-lactamase resistant cephamycin antibiotic, compared to cephalothin, cephaloridine and cefazolin].
    Schassan HH; Bentfeld G
    Fortschr Med; 1978 Aug; 96(30):1510-7. PubMed ID: 669547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of ceftizoxime and comparative compounds against Bacteroides fragilis in a mouse model of anaerobic infection.
    Grappel SF; Phillips L; Actor P
    J Antibiot (Tokyo); 1984 Apr; 37(4):384-8. PubMed ID: 6327593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
    Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
    Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenicity of capsulate and non-capsulate members of Bacteroides fragilis and B. melaninogenicus groups in mixed infection with Escherichia coli and Streptococcus pyogenes.
    Brook I
    J Med Microbiol; 1988 Nov; 27(3):191-8. PubMed ID: 2903934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor necrosis factor antibody reduces mortality in the presence of antibiotic-induced tumor necrosis factor release.
    Sawyer RG; Adams RB; May AK; Rosenlof LK; Pruett TL
    Arch Surg; 1993 Jan; 128(1):73-7; discussion 77-8. PubMed ID: 8418784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.